AC Immune Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	17.51	3.57	27.31	14.8	3.94	-
Revenue Growth	-39.45%	-86.92%	84.51%	276.14%	-74.50%	-
Cost of Revenue	45.91	56.44	62.57	54.61	60.34	62.28
Gross Profit	-28.41	-52.86	-35.26	-39.81	-56.4	-62.28
Selling, General & Admin	15.47	16.09	17.26	15.31	15.79	17.91
Other Operating Expenses	-0.18	-0.09	-0.14	-1.49	-1.34	-1.18
Operating Expenses	15.29	16	17.12	13.82	14.45	16.73
Operating Income	-43.7	-68.86	-52.38	-53.62	-70.85	-79.01
Interest Expense	-0.21	-0.19	-0.13	-0.18	-0.36	-0.58
Interest & Investment Income	1.12	1.87	3.2	1.04	0.07	6.49
Currency Exchange Gain (Loss)	0.09	-2.8	-1.6	-1.47	0.39	0.11
EBT Excluding Unusual Items	-42.7	-69.99	-50.91	-54.22	-70.74	-72.99
Merger & Restructuring Charges	-0.46	-0.46	-	-	-	-
Pretax Income	-43.16	-70.45	-50.91	-54.22	-70.74	-72.99
Income Tax Expense	-	-	0	0.01	0.01	0
Net Income	-43.16	-70.45	-50.92	-54.23	-70.75	-73
Net Income to Common	-43.16	-70.45	-50.92	-54.23	-70.75	-73
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	101	101	100	85	84	75
Shares Outstanding (Diluted)	101	101	100	85	84	75
Shares Change	1.25%	1.06%	17.71%	1.36%	11.48%	4.24%
EPS (Basic)	-0.43	-0.70	-0.51	-0.64	-0.85	-0.97
EPS (Diluted)	-0.43	-0.70	-0.51	-0.64	-0.85	-0.97
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-51.09	-70.16	65.27	-61.21	-74.81	-68.32
Free Cash Flow Per Share	-0.50	-0.70	0.66	-0.72	-0.90	-0.91
Gross Margin	-162.23%	-	-129.12%	-268.94%	-	-
Operating Margin	-249.58%	-1927.32%	-191.80%	-362.30%	-1800.43%	-
Profit Margin	-246.48%	-1971.65%	-186.44%	-366.41%	-1798.04%	-
Free Cash Flow Margin	-291.78%	-1963.67%	238.99%	-413.55%	-1901.07%	-
EBITDA	-42.48	-67.47	-50.89	-51.95	-69.05	-77.11
EBITDA Margin	-242.61%	-	-186.36%	-	-	-
D&A For EBITDA	1.22	1.39	1.49	1.67	1.79	1.9
EBIT	-43.7	-68.86	-52.38	-53.62	-70.85	-79.01
EBIT Margin	-249.58%	-	-191.80%	-	-	-
Revenue as Reported	17.51	3.57	27.31	14.8	3.94	-

SEC Filings: 10-K · 10-Q